181 related articles for article (PubMed ID: 33348781)
1. B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma.
Zi Z; Zhao H; Wang H; Ma X; Wei F
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348781
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.
Zheng M; Yu L; Hu J; Zhang Z; Wang H; Lu D; Tang X; Huang J; Zhong K; Wang Z; Li Y; Guo G; Liu S; Tong A; Yang H
Transl Oncol; 2020 May; 13(5):100770. PubMed ID: 32298986
[TBL] [Abstract][Full Text] [Related]
3. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W; Zhang M; Hu G; Han Y; Mao X; Chen C; Shen K; Dai Z; Zhu X; Zhou X; Huang L; Ao Q; Xiao M
Front Immunol; 2023; 14():1280007. PubMed ID: 38143760
[TBL] [Abstract][Full Text] [Related]
4. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Yamamoto R; Nishikori M; Tashima M; Sakai T; Ichinohe T; Takaori-Kondo A; Ohmori K; Uchiyama T
Cancer Sci; 2009 Nov; 100(11):2093-100. PubMed ID: 19703193
[TBL] [Abstract][Full Text] [Related]
5. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.
Tang X; Liu F; Liu Z; Cao Y; Zhang Z; Wang Y; Huang J; Fan S; Zhao S; Chen Y; Li G; Wang S; Zheng M; Hu Y; Li H; Jiang C; Yang M; Yang H; Xu J; Guo G; Tong A; Zhou L
Clin Transl Immunology; 2020; 9(6):e1137. PubMed ID: 32547742
[TBL] [Abstract][Full Text] [Related]
6. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
[TBL] [Abstract][Full Text] [Related]
7. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
[TBL] [Abstract][Full Text] [Related]
8. B7-H3-Targeting Chimeric Antigen Receptors Epstein Barr Virus Specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3 Positive Solid Tumors.
Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
Cancer Res Commun; 2024 May; ():. PubMed ID: 38717140
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
10. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
[TBL] [Abstract][Full Text] [Related]
11. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract][Full Text] [Related]
12. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
14. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
[TBL] [Abstract][Full Text] [Related]
15. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
[TBL] [Abstract][Full Text] [Related]
17. ALCL by any other name: the many facets of anaplastic large cell lymphoma.
Irshaid L; Xu ML
Pathology; 2020 Jan; 52(1):100-110. PubMed ID: 31706671
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
Front Oncol; 2021; 11():659662. PubMed ID: 34868903
[TBL] [Abstract][Full Text] [Related]
19. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
20. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
